Q J Med 2003; 96: 593-599
© 2003 Association of Physicians
Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven
From the 1Cardiac Clinic, Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa, 2Ministry of Public Health, BP 25125 Messa, Yaoundé, Cameroon, and 3School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
Received 7 April 2003 and in revised form 19 May 2003
Background: There is controversy regarding the effectiveness of corticosteroids in tuberculous pericarditis, particularly in patients who are immunocompromised by HIV.
Aim: To determine the effectiveness of adjuvant corticosteroids in tuberculous pericarditis.
Design: Systematic review of randomized controlled trials.
Methods: We searched the Cochrane Infectious Diseases Group trials register (June 2002), the Cochrane Controlled Trials Register (Issue 2, 2002), MEDLINE (January 1966 to March 2003), EMBASE (1980 to May 2002), and the reference lists of existing reviews, for randomized and quasi-randomized controlled trials of adjuvant corticosteroids in the treatment of suspected tuberculous pericarditis. We also contacted organizations and individuals working in the field. Two reviewers independently assessed trial quality and extracted data. We used meta-analysis with a fixed effects model to calculate the summary statistics, provided there was no statistically significant heterogeneity, and expressed results as relative risk.
Results: Four trials with a total of 469 participants met our criteria. Three (total n = 411) tested adjuvant steroids in participants with suspected tuberculous pericarditis in the pre-HIV era. Fewer participants died in the intervention group, but the potentially large reduction in mortality was not statistically significant (relative risk RR 0.65, 95%CI 0.36–1.16, n = 350; p = 0.14). One trial with 58 patients that enrolled HIV-positive individuals also showed a promising but non-significant trend on mortality (RR 0.50, 95%CI 0.19–1.28; p = 0.15). There was no significant beneficial effect of steroids on re-accumulation of pericardial effusion or progression to constrictive pericarditis. Patients with pericardial effusion were significantly more likely to be alive with no functional impairment at 2 years following treatment. However, the effect was not sustained in a sensitivity analysis that included patients who were lost to follow-up.
Discussion: Steroids could have large beneficial effects on mortality and morbidity in tuberculous pericarditis, but published trials are too small to be conclusive. Large placebo-controlled trials are required, and should include sufficient numbers of HIV-positive and HIV-negative participants, and an adequate adjuvant steroid dose.
Address correspondence to Dr B.M. Mayosi, The Cardiac Clinic, E25 Groote Schuur Hospital, Anzio Road, Observatory 7925, South Africa. e-mail: bmayosi{at}uctgsh1.uct.ac.za
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. M Mayosi Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa Heart, October 1, 2007; 93(10): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ntsekhe and J. Hakim Impact of Human Immunodeficiency Virus Infection on Cardiovascular Disease in Africa Circulation, December 6, 2005; 112(23): 3602 - 3607. [Abstract] [Full Text] [PDF]
|
|